Tvardi Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 31st day of March 2026.
| | | |
|---|---|---|
| | TVARDI THERAPEUTICS, INC. | |
| | | |
| | By: | /s/ Imran Alibhai |
| | Name: | Imran Alibhai |
| | Title: | Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Imran Alibhai and Dan Conn, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact, proxy and agents, and each ot them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | | |
|---|---|---|---|---|
| Signature | | Title | | Date |
| | | | | |
| /s/ Imran Alibhai | | Chief Executive Officer and Director | | March 31, 2026 |
| Imran Alibhai | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Dan Conn | | Chief Financial Officer | | March 31, 2026 |
| Dan Conn | | (Principal Financial Officer) | | |
| | | | | |
| /s/ Stephen O’Brien | | Vice President, Finance and Corporate Controller | | March 31, 2026 |
| Stephen O’Brien | | (Principal Accounting Officer) | | |
| | | | | |
| /s/ Sujal Shah | | Chairman of the Board of Directors | | March 31, 2026 |
| Sujal Shah | | | | |
| | | | | |
| /s/ Wallace Hall | | Director | | March 31, 2026 |
| Wallace Hall | | | | |
| /s/ Michael S. Wyzga | | Director | | March 31, 2026 |
| Michael S. Wyzga | | | | |
| | | | | |
| /s/ Cynthia Smith | | Director | | March 31, 2026 |
| Cynthia Smith | | | | |
| | | | | |
|---|---|---|---|---|
| /s/ Susan Shiff | | Director | | March 31, 2026 |
| Susan Shiff | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.